Drug intelligence / Profile preview

jwcar201

Development stage: Phase 1
Lead developer: JW Therapeutics
Modality: Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

JWCAR201 is an investigational autologous CAR-T cell therapy that targets both CD19 and CD20 antigens on B cells. It is designed for the treatment of B cell-driven hematologic malignancies and autoimmune diseases. The therapy involves engineering a patient's own T cells to express chimeric antigen receptors (CARs) specific for CD19 and CD20, enabling targeted immune-mediated destruction of malignant or autoreactive B cells. JWCAR201 is currently in Phase 1 clinical trials for indications including large B-cell lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and systemic lupus erythematosus[1][2][4]. The product is administered as a single intravenous infusion.

Other names: jwcar201jwcar-201jwcar 201autologous cd19/cd20-directed car-t cells

Targets

CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on jwcar201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jwcar201.

Explore the full profile